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Title: A large number of cutaneous neurofibromas beyond age-appropriate 
incidence in a patient with a large deletion of NF1.  
Neurofibromatosis 1 (NF1) is an autosomal genetic disease caused by mutations of the 
NF1 gene with a prevalence of approximately 1 in 3000 individuals.1 Until now, only a 
few genotype-phenotype correlations in NF1 have been identified.2 Although severity of 
NF1 are variable in degree, large NF1 deletions have been reported to be accompanied 
by more severe clinical symptom.3 We have already shown that the number of cutaneous 
neurofibromas significantly increases with age.4 Herein we focus on the relationship 
between the number of cutaneous neurofibromas and the type of NF1 mutation in 
consideration for each patient’s age. 
We studied 17 NF1 patients (4 men and 13 non-pregnant women; average age, 30.2 years; 
age range, 0-79 years) at the Dermatology Department of Tottori University Hospital 
from 2014 to 2016 after informed consent. All of the patients fulfilled the criteria for a 
diagnosis of NF1 by National Institutes of Health in 1988.5 Blood samples were sent to 
Keio University for genetic analysis of NF1. Genomic DNA was extracted from 
peripheral blood according to standard procedures. In-solution hybridization-based 
enrichment was performed using the SureSelect Target Enrichment system (Agilent 
Technologies, Santa Clara, CA, USA). When the next-generation sequencing protocol 
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revealed truncating mutations, the variants were validated by direct capillary sequencing 
methods. The exon deletions were screened using a multiple ligation-dependent probe 
amplification method (SALSA P081/082-B2 NF1MLPA assay kit; MRC-Holland). We 
also counted the number of cutaneous neurofibromas (> 5 mm in diameter) excluding 
subcutaneous neurofibromas by visual judgment. Clinical severity of each patient was 
evaluated by DNB classification.3 We investigated the relationship between the number 
of cutaneous neurofibromas and the type of mutations in detail. Ethics Committee of 
Tottori University Hospital approved the study protocol (No. G125). 
As reported previously,3 the number of cutaneous neurofibromas increased with age 
(Table 1). A patient No 13 (age, 47), in whom whole exon deletions were identified, had 
an extremely large number of neurofibromas beyond age-appropriate incidence (Fig. 1). 
She was accompanied by intellectual disability, hypertelorism and tall stature. Although 
small exon deletions were identified in patients 10 and 11, they showed age-appropriate 
number of neurofibromas. There was no evidence of association between each type of 
NF1 mutation and DNB classification. 
Large deletions of NF1 occur in about 5% of the patients and are associated with severe 
manifestations.2 It has been reported that patients with large NF1 deletions exhibited a 
very high number of cutaneous and subcutaneous neurofibromas, and increased 
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frequencies of spinal neurofibromas and malignant peripheral nerve sheath tumors.3 In 
addition, age is one of the most important factors in clinical manifestations of NF1. We 
have to keep in mind the influence of increasing age on the development of cutaneous 
neurofibromas. In this study, we found that a large number of cutaneous neurofibromas 
develop in a patient with a large NF1 deletion beyond age-appropriate incidence, which 
would be a clue for the diagnosis of severe phenotype of NF1. 
 
 
